Management and Prevention of Stroke Associated with Elevated Homocysteine

Area of Science:

• Neurology
• Vascular Medicine
• Nutritional Science

Background:

• Elevated homocysteine (Hcy) is associated with preclinical markers of cerebrovascular disease and ischemic stroke.
• The precise mechanisms linking Hcy to stroke remain under investigation, but proposed pathways include promotion of thrombosis and atherosclerosis.
• Plasma Hcy levels are sensitive indicators of deficiencies in folate, vitamin B12, and vitamin B6.

Purpose of the Study:

• To review the association between elevated homocysteine and cerebrovascular disease.
• To evaluate the efficacy of homocysteine-lowering strategies, particularly folic acid supplementation.
• To provide recommendations for primary and secondary stroke prevention based on current evidence.

Main Methods:

• Review of observational data from prospective and retrospective studies.
• Analysis of the impact of folic acid, vitamin B12, and vitamin B6 supplementation on plasma Hcy levels.
• Consideration of existing guidelines for stroke prevention.

Main Results:

• Folic acid supplementation is the most effective method for lowering mild-to-moderately elevated Hcy.
• Individuals with higher baseline Hcy or lower folate levels show the greatest reduction in Hcy with supplementation.
• Vitamin B12 offers a minor additional benefit, while vitamin B6 has not shown significant added value.
• Clinical trial outcomes for Hcy-lowering therapy in secondary stroke prevention are still pending.

Conclusions:

• Folic acid supplementation is a key strategy for reducing elevated homocysteine levels.
• Dietary intake of folate, B6, and B12 is recommended for primary stroke prevention.
• Supplemental multivitamins are advised for individuals with established cerebrovascular disease and hyperhomocysteinemia, pending further clinical trial results.